Home / Market News / $GUTS

$GUTS news and market catalysts

The 5 most recent market catalysts affecting $GUTS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

5 catalysts 5 high impact 3 bullish 2 bearish Biotechnology
Oct 16, 2026 Corporate Catalyst Bearish Impact 95
Why Fractyl Health Stock Is Sinking Friday
Fractyl Health (GUTS) experienced a dramatic stock decline of almost 50% despite announcing positive six-month clinical trial data for its Revita weight-loss treatment. The market'…
Oct 16, 2026 Corporate Catalyst Bullish Impact 85
Fractyl Health’s REMAIN-1 Study Meets Six-Month Co-Primary Endpoint With High Statistical Significance; Demonstrates 80% Retention Of GLP-1 Induced Weight Loss Vs 67% For Sham
Fractyl Health reported highly statistically significant positive six-month results from its REMAIN-1 study for the Revita DMR System. The study met its co-primary endpoint, demons…
Aug 10, 2026 Corporate Catalyst Bearish Impact 92
Fractyl Health Q2 EPS $(0.16) Misses $(0.13) Estimate
Fractyl Health (GUTS) announced its Q2 earnings, reporting a loss of $(0.16) per share, which was 23.08% wider than the analyst consensus estimate of $(0.13). This significant miss…
Jul 15, 2026 Corporate Catalyst Bullish Impact 85
Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars
Fractyl Health (GUTS) announced compelling one-year results for its Revita DMR System, demonstrating its ability to significantly reduce weight regain after patients stop GLP-1 obe…
Jul 15, 2026 Corporate Catalyst Bullish Impact 85
Fractyl Health shares are trading higher after the company announced randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation.
This announcement is a significant corporate catalyst for Fractyl Health, as positive clinical trial data, especially demonstrating durable results after drug discontinuation, can …
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.